Emtricitabine (Emtriva®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000462
English
Authors' recommendations:
Emtricitabine (Emtriva®) is recommended for use within NHS Wales as an option for the treatment of Human Immunodeficiency Virus (HIV-1) infected adults in combination with other antiretroviral agents for use in treatment-naïve patients in line with current BHIVA guidelines. It should only be prescribed by HIV specialists. AWMSG has
requested the manufacturers make a further submission relating to paediatric use.
Details
Project Status:
Completed
Year Published:
2007
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=85242&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Deoxycytidine
- Adenine
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.